Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea

Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant

(2023) Young Rock Jang et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19

(2023) Kevin E. Kip et al.   ANNALS OF INTERNAL MEDICINE

Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies

(2023) Mingtao Liu et al.   Frontiers in Microbiology

Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines

(2022) Queenie Fernandes et al.   ANNALS OF MEDICINE

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

(2022) Delphine Planas et al.   NATURE

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

(2022) Laura A. VanBlargan et al.   NATURE MEDICINE

In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein

(2022) Nabarun Chandra Das et al.   Frontiers in Immunology

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients with Mild-to-Moderate Coronavirus Disease 2019

(2022) Anca Streinu-Cercel et al.   Open Forum Infectious Diseases

Clinical Effectiveness of Regdanvimab Treatment for Mild to Moderate COVID-19: A Retrospective Cohort Study

(2022) Young Rock Jang et al.   CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL

Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis

(2022) Jiawen Deng et al.   INFECTION

Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score–matched retrospective cohort study

(2022) Shinwon Lee et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

(2022) Sho Iketani et al.   NATURE

Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19

(2022) Taeyun Kim et al.   Journal of Clinical Medicine

Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis

(2022) Mingyang Yang et al.   JOURNAL OF INFECTION

Timing of REGEN-COV administration and progression to severe COVID-19

(2022) Tomoka Kadowaki et al.   JOURNAL OF INFECTION AND CHEMOTHERAPY

Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial

(2022) Gary A Herman et al.   LANCET INFECTIOUS DISEASES

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab or Sotrovimab for Mild to Moderate Coronavirus Disease-2019

(2022) Raymund R. Razonable et al.   MAYO CLINIC PROCEEDINGS

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients with Mild-to-Moderate COVID-19

(2022) Jin Yong Kim et al.   Open Forum Infectious Diseases

Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients

(2022) Matthew K. Wynia et al.   CHEST

Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies

(2022) Juan C. Almagro et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Recent review of COVID-19 management: diagnosis, treatment and vaccination

(2022) Vivek P. Chavda et al.   Pharmacological Reports

Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

(2022) Ji-Min Seo et al.   Emerging Microbes & Infections

Increased reporting of venous and arterial thromboembolic events reported with tixagevimab–cilgavimab for coronavirus disease 2019

(2022) François Montastruc et al.   CLINICAL MICROBIOLOGY AND INFECTION

Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19

(2022) Jingrui Zou et al.   Pharmaceuticals

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

(2021) Robert L. Gottlieb et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

(2021) Cheolmin Kim et al.   Nature Communications

COVID-19 vaccine challenges: What have we learned so far and what remains to be done?

(2021) Rebecca Forman et al.   HEALTH POLICY

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant

(2021) Dong-Kyun Ryu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Tackling COVID-19 with neutralizing monoclonal antibodies

(2021) Davide Corti et al.   CELL

Reactions and COVID-19 disease progression following SARS-CoV-2 monoclonal antibody infusion

(2021) Laurel Goldin et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Informing selection of drugs for COVID-19 treatment through adverse events analysis

(2021) Wenjing Guo et al.   Scientific Reports

Current status of therapeutic monoclonal antibodies against SARS-CoV-2

(2021) Sanjeev Kumar et al.   PLoS Pathogens

The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2

(2021) Dong-Kyun Ryu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Regdanvimab: First Approval

(2021) Yahiya Y. Syed   DRUGS

Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease

(2021) Ji Yeon Lee et al.   Frontiers in Immunology

The COVID-19 Pandemic: A Global Health Crisis

(2020) Casey A. Pollard et al.   PHYSIOLOGICAL GENOMICS

Examining the Use of Real‐World Evidence in the Regulatory Process

(2019) Brett K. Beaulieu‐Jones et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS